



November 12, 2022

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Newspaper cutting of extract of consolidated financial results for quarter ended on September 30, 2022

Enclosed please find newspaper cutting of extract of consolidated financial results for the quarter ended on September 30, 2022 published in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI circular bearing reference no. CIR/CFD/FAC/62/2016 dated July 5, 2016 in Business Standard and Sakal edition of November 12, 2022.

Thanking you,

Yours faithfully,
For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President - Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

HEALTHCARE GLOBAL ENTERPRISES LIMITED
CIN: L15200KA1998PLC023489
Regd Off: HCG Towers, # 8, P Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560027, Karnataka, India
Corporate Office: Unity Buildings Complex, No. 3, Tower Block, Ground Floor, Mission Road, Bangalore - 560027, Karnataka, India Phone: +91 - 80 - 4660 7700, Fax: +91 - 80 - 4660 7749 Email: investors@hcgcnology.com; Website: www.hcgcnology.com



EXTRACT OF THE UNAUDITED CONSOLIDATED & STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER 2022

Particulars	Consolidated (Amount in Rs. Lakhs)			Standalone (Amount in Rs. Lakhs)		
	Quarter ended 30 September 2022	Preceding quarter ended 30 June 2022	Corresponding quarter ended 30 September 2021	Quarter ended 30 September 2022	Preceding quarter ended 30 June 2022	Corresponding quarter ended 30 September 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
Total income	42,197	41,096	35,526	25,434	24,504	21,720
Net (loss)/profit for the period/year (before tax and exceptional items)	1,002	1,042	179	1,392	1,641	728
Exceptional items, net gain	-	-	14,012	-	-	12,542
Profit before tax	1,002	1,042	14,191	1,392	1,641	13,270
Net profit for the period/year (after tax and exceptional items)	529	248	9,899	1,100	1,085	9,390
Net profit for the period/year attributable to equity share holders of the company	738	605	10,309	1,100	1,085	9,390
Total comprehensive income for the period/year (Comprising net profit and other comprehensive income after tax)	765	680	10,092	1,100	1,085	9,390
Equity share capital	13,908	13,902	12,542	13,908	13,902	12,542
Earnings per share (of Rs.10 each) in Rs. Basic:	0.53	0.44	8.22	0.79	0.78	7.49
Earnings per share (of Rs.10 each) in Rs. Diluted:	0.53	0.43	7.69	0.79	0.78	7.00

Notes:
1. The above results were reviewed by the audit committee and approved by the board of directors at their meeting held on 10 November 2022.
2. The above is an extract from the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and the Company (www.hcgcnology.com).

For HealthCare Global Enterprises Limited
Dr. B. S. Ajaikumar
Executive Chairman

Bengaluru, 10 November 2022

Particulars	Standalone Result					
	3 Months ended		Preceding 3 months ended		For the year ended	
	30-09-2022	30-06-2022	30-09-2021	30-09-2021	30-09-2021	31-03-2022
1. Total Income from operations	8.07	8.07	11.26	16.14	12.66	32.04
2. Net Profit / (Loss)	5.98	3.48	0.36	9.46	1.45	13.91
3. Net Profit / (Loss) before tax (after Exceptional and/or Extraordinary Items)	5.98	3.48	0.36	9.46	1.45	13.91
4. Net Profit / (Loss) after tax (after Exceptional and/or Extraordinary Items)	5.98	3.48	0.36	9.46	1.45	12.04
5. Total Comprehensive Income for the period (after tax) (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	5.98	3.48	0.36	9.46	1.45	12.04
6. Equity Share Capital (Face Value of Rs. 10/- each)	125.00	125.00	125.00	125.00	125.00	125.00
7. Other Equity (as shown in the audited balance sheet of PFI)	-	-	-	-	-	-
8. Earnings Per Share (of Rs. 10/- each) (not annualised) Basic:	0.48	0.28	0.03	0.76	0.12	0.96
Diluted:	-	-	-	-	-	-

Notes:
1. The above is an extract of the detailed format of Quarterly and Year Ended to date financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results for the Quarter & Year ended 30th September, 2022 are available on the Stock Exchange's website.
2. The above results have been prepared by the Board of Directors in their meeting held on 11th Nov 2022.
3. The above results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015, as amended.
4. The company has received nil complaint from shareholders during the year ended on 30.09.2022.
5. Provision for taxation will be made at the end of the year

Krishnan Kannan-Director
DIN - 00014414

Date: November 11, 2022



GOODRICKE GROUP LIMITED
CIN-L01132WB1977PLC031054

Registered Office: 'Camellia House', 14, Gurusaday Road, Kolkata 700 019

Telephone: (033)2287-3067 / 2287-8737 / 2287-1816

Fax: (033) 2287-2577 / 2287-7089

Email: goodricke@goodricke.com Website: www.goodricke.com

Extract of the statement of standalone unaudited financial results for the quarter and half year ended 30th September 2022

Particulars	(Rs. in Lacs)		
	3 Months ended 30.09.2022	6 Months ended 30.09.2022	3 Months ended 30.09.2021
1 Revenue from operations	28044	47538	27596
2 Profit before tax	5357	6063	5543
3 Net profit after tax	3965	4522	5543
4 Total comprehensive income for the period (comprising profit for the period after tax and other comprehensive income after tax)	3932	4472	5443
5 Paid up equity share capital	2160	2160	2160
6 Other equity	-	-	30084
			(as on 31.03.2022)
7 Earnings per share of Rs.10/- each (basic and diluted)	18.36	20.94	25.66

The above is an extract of the detailed format of Quarterly results filed with the stock exchange under regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the BSE Limited website (www.bseindia.com) and on the website of the Company (www.goodricke.com)

The Standalone Unaudited Financial Results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 11th November, 2022.

For Goodricke Group Limited
A. Asthana
Managing Director & CEO
(DIN- 00631932)

Place : Kolkata
Date : November 11, 2022

MAHINDRA & MAHINDRA LIMITED

Registered Office: Gateway Building, Apollo Bunder, Mumbai - 400 001.

Tel: +91 22 22021031 • Fax: +91 22 22875485 • Website: www.mahindra.com

Email: group.communications@mahindra.com • CIN: L65990MH1945PLC004558

Extract of Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2022

Rs. in Crores

Particulars	Standalone		Consolidated			
	Quarter ended		Quarter ended		Half Year ended	
	30 th Sep 2022	30 th Sep 2021	30 th Sep 2022	30 th Sep 2022	30 th Sep 2021	30 th Sep 2022
Total income from operations	20,839.27	13,314.38	40,451.91	29,870.38	21,469.80	58,282.76
Net Profit/(loss) for the period (before tax and exceptional items)	2,982.99	2,143.22	4,812.18	3,236.91	3,481.19	6,112.95
Net Profit/(loss) for the period (before tax and after exceptional items)	2,735.13	1,888.22	4,523.35	3,943.05	3,445.08	6,837.01
Net Profit for the period (after tax and after exceptional items attributable to the owners of the Company)	2,089.92	1,433.45	3,520.08	2,772.73	1,928.64	4,968.27
Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax), attributable to the owners of the Company]]	2,102.66	1,436.10	3,553.46	2,641.90	1,949.55	4,721.63
Equity Share Capital	598.48	597.69	598.48	556.24	555.45	556.24
Earnings Per Share (not annualised) (Face value Rs. 5/- per share)						
Basic :	17.46	11.99	29.41	24.93	17.35	44.67
Diluted:	17.39	11.95	29.30	24.80	17.26	44.45

Notes:

1. The above is an extract of the detailed format of Statement of Standalone and Consolidated unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website viz. www.mahindra.com and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

2. Previous period figures of standalone results have been restated to include the effect of merger of Mahindra Engineering and Chemical Products Limited, Retail Initiative Holdings Limited and Mahindra Retail Limited with the Company.

For and on behalf of the Board of Directors

Dr. Anish Shah

Managing Director & CEO

Date: 11th November, 2022

Place: Mumbai

118-4023



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Corporate Office: Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor

Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400 025.

Phone: 022-2439 5200 / 2439 5500 Fax : 022-2431 5331 / 2431 5334

CIN : L24390MH1976PLC019380 Website: www.jbpharma.com E-mail : secretarial@jbpharma.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30/09/2022

(₹ in lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended 31/03/2022
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	80,944	78,481	59,301	159,425	119,900	242,424
2	Net Profit for the period before tax	14,983	14,174	12,943	29,157	28,730	50,490
3	Net Profit for the period after tax	11,108	10,520	9,789	21,628	21,695	38,604
4	Total Comprehensive Income for the period after tax	9,940	10,570	9,060	20,510	21,300	39,005
5	Equity Share Capital	1,547	1,546	1,546	1,547	1,546	1,546
6	Reserves	-	-	-	-	-	211,867
7	Earnings per share (EPS) (of ₹ 2/- each)						
	Basic:	*14.37	*13.59	*12.65	*27.96	*28.03	49.86
	Diluted:	*14.26	*13.56	*12.63	*27.75	*28.01	49.82

* Not Annualised
Notes

1. The key performance figures of standalone unaudited financial results for the quarter and six months ended 30/09/2022 are as under:

(₹ in lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended 31/03/2022
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	73,996	71,613	52,673	145,609	107,303	218,988
2	Net Profit for the period before tax	13,220	13,701	11,766	26,921	27,048	47,129
3	Net Profit for the period after tax	9,772	10,129	8,840	19,901	20,371	36,100

2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2022.

3. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites viz. www.bseindia.com and www.nseindia.com and the Company's website www.jbpharma.com.

For J. B. Chemicals & Pharmaceuticals Ltd.

Ranjit Shahani

Chairman

Date : November 11, 2022

Place : Mumbai

MANUGRAPH INDIA LIMITED



Registered Office: Sidhwa House, 2nd Floor, N. A. Sawant Marg, Colaba, Mumbai - 400 005.

CIN: L29290MH1972PLC015772; Tel. No.: 022-22874815 / 0620 Fax No.: 022-22870702

Email: sharegrievances@manugraph.com; Website: www.manugraph.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022

(Rs. in crores except EPS)

SR. NO.	PARTICULARS	Quarter ended	Half Year ended	Quarter ended
		30-09-2022 (Reviewed)	30-09-2022 (Reviewed)	30-09-2021 (Reviewed)
1.	Total income from Operations	25.79	31.89	16.81
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(3.41)	(8.68)	(3.16)
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(3.41)	(8.68)	(3.16)
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(3.50)	(8.92)	(3.19)
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(3.54)	(8.99)	(3.25)
6.	Equity Share Capital	-	6.08	-
7.	Other Equity	-	-	-
8.	Earnings Per Share of Rs. 2/- (Not annualised) Before exceptional item - Basic and diluted (Rs.)	(1.15)	(2.93)	(1.04)
9.	Earnings Per Share of Rs. 2/- (Not annualised) After exceptional item - Basic and diluted (Rs.)	(1.15)	(2.93)	(1.04)

Key Information on Standalone Unaudited Financial Results: (Rs. in crores)

SR. NO.	PARTICULARS	Quarter ended	Half Year ended	Quarter ended
		30-09-2022 (Reviewed)	30-09-2022 (Reviewed)	30-09-2021 (Reviewed)
1.	Total income from Operations	25.79	31.89	16.81
2.	Profit / (Loss) Before Tax	(3.41)	(8.68)	(3.16)
3.	Profit / (Loss) After Tax	(3.50)	(8.92)	(3.19)
4.	Total Comprehensive Income / (Loss)	(3.54)	(9.01)	(3.25)

NOTE:

The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2022 are available on the Stock Exchange websites (www.bseindia.com / www.nseindia.com) and Company's website www.manugraph.com

On Behalf of the Board

For Manugraph India Limited

Sanjay Shah

Chairman & Managing Director

Place : Mumbai

Date : November 11, 2022

८० तास काम कया

एलॉन मस्क यांचा कर्मचाऱ्यांना सल्ला

सॅनफ्रान्सिस्को, ता. ११ (वृत्तसंस्था) : आगामी दिवस कटीग असल्यामुळे कर्मचाऱ्यांनी घरातून काम करण्याची वेळ बंद करून कार्यालयात कामाला यावे आणि आठवड्याचे ८० तास काम करावे, असा इशारा ट्विटरचे नवे सर्वेसर्वा एलॉन मस्क यांनी बुधवारी (ता. १०) कर्मचाऱ्यांच्या पहिल्या बैठकीत दिला.



कंपनीच्या येथील मुख्यालयात घेतलेल्या बैठकीत त्यांनी अनेक कटोर निर्णयांचे सुतोवाच केले. मस्क यांनी आधी कर्मचाऱ्यांना ई-मेल पाठवून कार्यालयात ४० तास काम करण्याचे आवाहन केले होते व पुढील दिवस कटीग असल्याचा इशारा दिला होता. या इशाराचा या बैठकीत त्यांनी पुनरावलोकन केले व कर्मचाऱ्यांना ८० तास काम करण्यास बजावले.

कर्मचाऱ्यांना अन्य सवलतीदेखील फार कमी मिळतील, असेही त्यांनी सुनावले.

घरून काम करण्याची कर्मचाऱ्यांना मिळणारी सोय बंद करण्याचेही त्यांनी समर्थन केले. यासंदर्भातील कर्मचाऱ्यांचा प्रसाला उत्तर देताना मस्क चांगलेच भडकले होते, असे काही कर्मचाऱ्यांनी ट्विट करून सांगितले आहे. यापुढे आपल्याला अत्यंत कटोरपणे मेहनत करावी लागणार आहे, तुम्ही ते करू शकत नसाल तर तुम्हाला ट्विटरमध्ये काहीही स्थान राहणार नाही, असेही मस्क यांनी स्पष्ट केले आहे.

मुंबईत पोटच्या मुलाला आईने विकले

मुंबई, ता. ११ : एक दिवसाच्या रात्री बेड्या ठोकल्या. पोलिसांनी मुलीला विकण्याचा डाव उघडून दिलेल्या माहितीनुसार, मुलाची खोदी लावत पोलिसांनी बाळाची सुबक करणारी महिला ही पेशाने नर्स आहे; सुटका केली आहे. या प्रकरणी बाळाची खोदी करणाऱ्या नर्ससह आरोपी आई असून ती बेरोजगार आहे. पोलिसांनी आईला गुरुवारी (ता. ११)

TATA AIG
टाटा एआयजी जनरल इन्शुरन्स कंपनी लिमिटेड
 नोंदीकृत कार्यालय : पेनिन्सुला बिझनेस पार्क, टॉप ए, १५ वा मजला, गणसतारक कवय माग, लोअर पोल, मुंबई - ४० ००१३
 ब्र. : ०२२ - ६६६९१७६१ / फॅक्स : ०२२ - ६६६४६४६४
 ई-मेल : secretarial@department.tataaig.com वेबसाइट : www.tataaig.com
 सीआयएन : U85110MH2000PLC128425

सूचना
 याद्वारे सूचना देण्यात येत आहे की, कंपनीद्वारे जारी व दि. १९ डिसेंबर, २०२१ रोजी विमोचनयोग्य असलेल्या दि. १९ डिसेंबर, २०२२ रोजीनुसार अप्रतिभूत, दुय्यम, सूचिबद्ध, विमोचनयोग्य, बिगारपरीवर्तनीय पूर्णतः प्रदानित डिसेंबर देय ८.८५ टक्के (८.८५%) दराने वार्षिक व्याज प्राप्त करण्यासाठी पात्र असलेल्या कंपनीच्या कर्जरोखे डिसेंबरधारकांच्या पात्रतेच्या निश्चितीसाठी शनिवार, दि. ४ डिसेंबर, २०२२ ही तारीख नोंद दिनांक म्हणून निश्चित करण्यात आली आहे.

कर्जरोखेधारकांनी कृपया कंपनीचे रजिस्ट्रार व ट्रान्सफर एजंट, एनएसडीएल डेटाबेस मॅनेजमेंट लिमिटेड यांना, लागू असल्यानुसार कर्जरोखेधारकांचे संपूर्ण नाव, पत्ता, क्लायंट आयडी व डीपी आयडी लागू असल्याप्रमाणे नमूद करून सर्व भविष्यकालीन पत्रव्यवहार, कर्जरोखेधारकील व्याजासंदर्भात तसेच पत्त्यातील बदलांची सूचना द्यावी.

टाटा एआयजी जनरल इन्शुरन्स कंपनी लिमिटेड
 सही/-
 आशिष शर्मा
 कंपनी सचिव

ठिकाण : मुंबई
 दिनांक : १२.११.२०२२

Pfizer
फायझर लिमिटेड
 CIN: L24231MH1950PLC008311
 द कॉर्पोरेट, 1802/1901, प्लॉट क्र. C-70, जी- ब्लॉक, गॅरेज कुर्ला कॉम्प्लेक्स, गॅरेज (E), मुंबई 400 051
 कूरुवनी: +91 22 6693 2000 फॅक्स: +91 226254 0274
 ई-मेल आयडी: contactus.india@pfizer.com वेबसाइट: www.pfizeritd.co.in

३० सप्टेंबर २०२२ रोजी संपलेल्या तिमाही आणि अर्ध वर्षासाठी अलेखापरिचित आर्थिक परिणामांचा विधानाचा उतारा
 (प्रति शेअर कमाई व्यतिरिक्त ₹ कोटीमध्ये)

तपशील	३० सप्टेंबर २०२२ रोजी संपलेली तिमाही	३० सप्टेंबर २०२२ रोजी संपलेली चालू वर्षासाठी तारीख निहाय वर्ष	३० सप्टेंबर २०२१ रोजी संपलेले संवधित ३ महिने
१. एकूण उत्पन्न	६६९.७९	९२७२.६३	६५९.२९
२. तिमाही / कालवधीसाठी निव्वळ नफा (कर पूर्व, अपवादाल्पक आणि/किंवा असाधारण वस्तू)	२२६.३०	४०६.०२	९७४.९६
३. तिमाही / कालवधीसाठी करपूर्वी निव्वळ नफा (अपवादाल्पक आणि/किंवा असाधारण वस्तू पश्चात)	४९५.२२	४५८.६९	९७४.९६
४. तिमाही / कालवधीसाठी कर पश्चात निव्वळ नफा (अपवादाल्पक आणि/किंवा असाधारण आयटम पश्चात)	३९९.०७	३४३.६२	९४२.९५
५. तिमाही / कालवधीसाठी एकूण सर्वसमावेशक उत्पन्न (या कालवधीसाठी समावेशक नफा (कर पश्चात) आणि इतर सर्वसमावेशक उत्पन्न (कर पश्चात))	३९०.८७	३४३.२३	९४३.९०
६. इन्विस्टी शेअर कॅपिटल (समभाग मांडवळ)	४४.७५	४४.७५	४४.७५
७. रिझर्व्स अर्थात राखीव (पुनर्मुल्यांकन राखीव वगळून) मागील वर्षाच्या तालबंदीत दाखलव्याप्रमाणे	-	-	-
८. प्रति शेअर कमाई (₹/- प्रत्येकी) (वार्षिक नाही) *	६७.९९*	७५.९९*	३९.२५*
डायल्युटेड:	६७.९९*	७५.९९*	३९.२५*

टीप : १. उपरोक्त उतारा हा SEBI (सूचीबद्ध दायित्व आणि प्रकटीकरण आवश्यकता) विनियम, २०१५ च्या नियमन ३३ अंतर्गत स्टॉक एक्सचेंजमध्ये दाखल केलेल्या त्रैमासिक आर्थिक निकालांच्या तपशीलवार स्वरूपाचा एक उतारा आहे. त्रैमासिक आर्थिक निकालांचे संपूर्ण स्वरूप स्टॉक एक्सचेंजच्या पुढील वेबसाइट्स www.bseindia.com आणि www.nseindia.com आणि www.pfizeritd.co.in वर उपलब्ध आहे. तसेच कंपनीच्या www.pfizeritd.co.in या वेबसाइटवरही उपलब्ध आहे

फायझर लिमिटेडसाठी
 ए. श्रीधर
 व्यवस्थापकीय संचालक

११ नोव्हेंबर २०२२

राजीव यांच्या मारेकऱ्यांची मुक्तता

पान १ वरून येथे धनु नावाच्या महिला आत्मघातकी हल्लेखोराणे हत्या केली होती. निवडणूक सभेवेळी लिबेरेशन टायगर ऑफ तमिल इलमची (एलटीटीई) महिला दहशतवादी धनु (तेनमोजी राजलम) हिने राजीव गांधींना फुलांचा हार घातल्यानंतर त्यांच्या पायाला स्पर्श केला आणि खाली वाकून कपरेला बांधलेल्या स्फोटकांचा स्फोट केला. हा स्फोट एवढा जोरदार होता की अनेकांचे तुकडे झाले. राजीव गांधी आणि हल्लेखोर धनु यांच्यासह १६ जणांचा जागीच मृत्यू झाला, तर ४५ जण गंभीर जखमी झाले होते. राजीव यांनी त्यांच्या कार्याळात श्रीलंकेत शांतिसेना पाठवली होती. या शांतिसेनाला लिबेरेशन टायगर ऑफ तमिल इलम या तमिळ बंडखोरांचा विरोध होता. त्यातूनच हा आत्मघातकी हल्ला घडवून आणला होता.

या प्रकरणी नलिनी, रामचंद्रन, संधान, मुगन, पेरारीवलन, रॉबर्ट पायस आणि जयकुमार या योर्पाना जमरटोपेची शिक्षा टोटावण्यात आली होती. घटनेच्या कालम १४२ मधील विशेषाधिकाराचा वापर करत सर्वोच्च न्यायालयाने पेरारीवलनची सुमारे ३० वर्षांनंतर सुटका करण्याचे आदेश यावर्षी २१ मे रोजी दिले होते.

सोनियांनी नलिनीला केले होते माफ

राजीव गांधी यांच्या हत्येप्रकरणी नलिनीला अटक झाली तेव्हा ती गर्भवती होती. तिला गरोदर होऊन दोन महिने झाले होते. त्यानंतर सोनिया गांधींनी नलिनीला माफ केले. नलिनीच्या चुकीची शिक्षा अद्याप जगतात न आलेल्या एका निष्पाप बाळाला कशी दिली जाऊ शकते, असे त्या म्हणाल्या होत्या.

UNICHEM LABORATORIES LTD.
 CIN:L99999MH1962PLC012451
 Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai - 400 102
 Website: www.unichemlabs.com; E-mail Id: shares@unichemlabs.com;
 Tel.: (022) 6688 8333

EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022

Sr. No.	Particulars	Quarter ended 30 th Sep'22	Quarter ended 30 th Jun'22	Quarter ended 30 th Sep'21	Six months ended 30 th Sep'22	Six months ended 30 th Sep'21	Year ended 31 st Mar'22
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	26,563.83	24,478.13	21,696.73	51,041.96	41,777.04	94,292.66
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(4,982.93)	(2,327.91)	(2,658.98)	(7,310.84)	(6,297.28)	(8,674.77)
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(5,485.17)	(2,327.91)	(2,658.98)	(7,813.08)	(6,297.28)	(8,674.77)
4	Net Profit / (Loss) for the period after tax (after exceptional items)	(7,546.39)	(2,327.91)	(2,143.32)	(9,874.30)	(4,928.18)	(5,542.96)
5	Total comprehensive income for the period (comprising of profit / loss for the period (after tax) and other comprehensive income (after tax))	(3,916.45)	(2,121.75)	(2,361.98)	(6,038.20)	(5,168.44)	(5.76)
6	Paid-up Equity Share Capital	1,408.12	1,408.12	1,408.12	1,408.12	1,408.12	1,408.12
7	Other Equity [Reserves excluding Revaluation Reserve]	-	-	-	-	-	2,65,795.97
8	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)	(10.72)	(3.31)	(3.04)	(14.02)	(7.00)	(7.87)
(a)	Basic	(10.72)	(3.31)	(3.04)	(14.02)	(7.00)	(7.87)
(b)	Diluted	(10.72)	(3.31)	(3.04)	(14.02)	(7.00)	(7.87)

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022

Sr. No.	Particulars	Quarter ended 30 th Sep'22	Quarter ended 30 th Jun'22	Quarter ended 30 th Sep'21	Six months ended 30 th Sep'22	Six months ended 30 th Sep'21	Year ended 31 st Mar'22
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	32,881.93	30,960.83	29,066.08	63,842.76	58,857.34	1,26,983.22
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(4,223.05)	(2,067.46)	(1,551.20)	(6,290.51)	(2,455.34)	2,196.89
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(4,725.29)	(2,067.46)	(1,551.20)	(6,792.75)	(2,455.34)	2,196.89
4	Net Profit / (Loss) for the period after tax (after exceptional items)	(7,066.63)	(2,336.87)	(1,281.68)	(9,403.50)	(2,430.56)	3,306.17
5	Total comprehensive income for the period (comprising of profit / loss for the period (after tax) and other comprehensive income (after tax))	(2,933.98)	(1,651.47)	(1,552.37)	(4,585.45)	(2,716.76)	8,681.22
6	Paid-up Equity Share Capital	1,408.12	1,408.12	1,408.12	1,408.12	1,408.12	1,408.12
7	Other Equity [Reserves excluding Revaluation Reserve]	-	-	-	-	-	2,60,432.98
8	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)	(10.04)	(3.32)	(1.82)	(13.36)	(3.45)	4.70
(a)	Basic	(10.04)	(3.32)	(1.82)	(13.36)	(3.45)	4.68
(b)	Diluted	(10.04)	(3.32)	(1.82)	(13.36)	(3.45)	4.68

Notes:

- The standalone financial results for the quarter and half year ended 30th September, 2022 and consolidated financial results for the quarter and half year ended 30th September 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2022. The statutory auditors have carried out a limited review of the standalone and consolidated financial results. The above is an extract of the detailed format of the unaudited standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated unaudited financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.
- The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

Particulars	Quarter ended 30 th Sep'22	Quarter ended 30 th Jun'22	Quarter ended 30 th Sep'21	Six months ended 30 th Sep'22	Six months ended 30 th Sep'21	Year ended 31 st Mar'22
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total R&D expenditure	2,957.07	2,205.28	2,520.04	5,162.35	5,617.74	11,274.10

By Order of the Board
 For Unichem Laboratories Limited
 SD/-
 Dr. Prakash A. Mody
 Chairman & Managing Director
 DIN : 00001285

Place: Mumbai
 Date: 11th November, 2022

J. B. CHEMICALS & PHARMACEUTICALS LIMITED
 Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office: Cnergy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor
 Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022-2431 5331 / 2431 5334
 CIN : L24390MH1976PLC019380 Website: www.jbpharma.com E-mail : secretarial@jbpharma.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30/09/2022
 (₹ In lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended 31/03/2022
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	80,944	78,481	59,301	159,425	119,900	242,424
2	Net Profit for the period before tax	14,983	14,174	12,943	29,157	28,730	50,490
3	Net Profit for the period after tax	11,108	10,520	9,789	21,628	21,695	38,604
4	Total Comprehensive Income for the period after tax	9,940	10,570	9,060	20,510	21,300	39,005
5	Equity Share Capital	1,547	1,546	1,546	1,547	1,546	1,546
6	Reserves	-	-	-	-	-	211,867
7	Earnings per share (EPS) (of ₹ 2/- each)						
	Basic:	*14.37	*13.59	*12.65	*27.96	*28.03	49.86
	Diluted:	*14.26	*13.56	*12.63	*27.75	*28.01	49.82

* Not Annualised
Notes
 1. The key performance figures of standalone unaudited financial results for the quarter and six months ended 30/09/2022 are as under:

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended 31/03/2022
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	73,996	71,613	52,673	145,609	107,303	218,988
2	Net Profit for the period before tax	13,220	13,701	11,766	26,921	27,048	47,129
3	Net Profit for the period after tax	9,772	10,129	8,840	19,901	20,371	36,100

2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2022.
 3. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites viz. www.bseindia.com and www.nseindia.com and the Company's website www.jbpharma.com.

For J. B. Chemicals & Pharmaceuticals Ltd.
 Ranjit Shahani
 Chairman

Date : November 11, 2022
 Place : Mumbai